Indian Drug Firms

MK Hamied steps down as Cipla's Vice Chairman on account of age, health

Drug major Cipla on Tuesday said MK Hamied has resigned as Vice Chairman with effect from October 29 due to age and health. "It is with a heavy heart that I write to formally announce my resignation from the position of Vice Chairman and Non-Executive Director of the company," he said in a letter to the board of directors. The company said the board has also approved the appointment of Kamil Hamied as Non-Executive Director, with effect November 1, 2024. "I am pleased to see that Kamil Hamied will be joining the Board as a Non-Executive Director to maintain continuity while representing the promoter family," MK Hamied said in the letter.

Domestic drugs formulations market to be worth Rs 5.5 trn by 2034: Report

'Significant under-penetration' in domestic market, especially in smaller towns and rural areas

Ayushman Bharat, Schedule M on health ministry and DoP's top agenda

Industry sources say Centre is considering increasing coverage under Ayushman Bharat scheme to Rs 10 lakh from the current Rs 5 lakh

Oppn protests over drug menace, claims ministers shielding Lalit Patil

Leaders from the Opposition parties staged a protest against the Maharashtra government over the drug menace in the state, and alleged that some ministers were shielding drug racketeer Lalit Patil. Leaders from the Maha Vikas Aghadi (MVA), comprising the Shiv Sena (UBT), Nationalist Congress Party's Sharad Pawar faction and the Congress, gathered on the steps of the Vidhan Bhavan here and raised slogans against the government. Leader of opposition in the legislative assembly Vijay Wadettiwar, leader of opposition in the council Ambadas Danve, MLC Satej Patil and several other legislators took part in the protest. "The youth of Maharashtra is getting addicted to drugs, and the state is on the verge of becoming 'Udta Maharashtra' like 'Udta Punjab'," said Wadettiwar, referring to the 2016 Bollywood film about a drug crisis in the northern state. Talking to reporters, the Congress leader alleged that some ministers were shielding drug racketeer Lalit Patil and demanded action against

Drug regulator CDSCO finds syrups made by Norris Medicines toxic: Report

The drug regulator for Gujarat state, where Norris is based, told Reuters that its factory had been closed

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Bayer brings kidney disease treatment drug to India at 1/15th US cost

Brand named Kerendia (finerenone) will cost Rs 97.5 per day as treatment cost in India

I-T dept raids Delhi-Haryana pharma and realty cos; seizes cash and gold

Finds links to Hawala sale of medicines to Afghanistan

Our goal is to have HPV vaccination as part of State mission: MSD India MD

In a Q&A, Rehan A Khan talks about his firm's strong focus on R&D and its commitment to making drugs affordable

Top 300 drug brands to have QR codes on label for ensuring authenticity

The Union Ministry of Health has made amendments to the Drugs Rules, 1945, to implement this

Govt engaging with drug makers to ramp up production of anti-fungal drug

The government is engaging with the drug manufacturers to ramp up the production of an antifungal drug used for the treatment of mucormycosis, says Chemicals and Fertilizers Ministry

Indian drugmaker Fresenius Kabi sentenced to pay $50 million in US fines

The company pleaded guilty to concealing and destroying records prior to a 2013 US Food and Drug Administration (FDA) plant inspection, the Department of Justice said

Patanjali refutes IMA's claims; releases research papers on Coronil

To support its argument, Patanjali has released a bunch of scientific papers on its research for a Covid-19 medicine that was published in popular peer-reviewed journals

India's leading drugmakers stocking up to avoid supply disruptions

Have increased raw material buffer stock by at least 40 days in recent months

From Sun Pharma to Biocon, US to remain a challenge for Indian drug firms

Indian firms with specialty product portfolios will do better than peers

Sales decline in US pushes drug makers to evaluate better options in Europe

Europe is the third-largest market for Indian drug makers after the US and Africa